GlycoMimetics Inc. (GLYC) had a rough trading day for Thursday November 21 as shares tumbled 16.88%, or a loss of $-1.08 per share, to close at $5.32. After opening the day at $5.74, shares of GlycoMimetics Inc. traded as high as $5.74 and as low as $4.73. Volume was 795,473 shares over 7,548 trades, against an average daily volume of n/a shares and a total float of 43.36 million.
As a result of the decline, GlycoMimetics Inc. now has a market cap of $230.67 million. In the last year, shares of GlycoMimetics Inc. have traded between a range of $13.56 and $2.64, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.
GlycoMimetics Inc. is based out of Rockville, MD and has some 50 employees. Its CEO is Rachel K. King.
